Welcome to our dedicated page for Citius Oncology SEC filings (Ticker: CTOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Citius Oncology, Inc. (Nasdaq: CTOR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an emerging growth company incorporated in Delaware and listed on Nasdaq, Citius Oncology reports material corporate events, governance decisions, and securities transactions through forms such as 8‑K, proxy statements, and registration-related documents.
Recent Form 8‑K filings describe events including amendments to the company’s 2024 Omnibus Stock Incentive Plan and unregistered sales of equity securities. For example, Citius Oncology has reported an increase in the number of shares of common stock authorized for issuance under the 2024 Omnibus Stock Incentive Plan and the issuance of warrants to a financial advisor in a private placement. Another 8‑K details stockholder voting results at the 2025 annual meeting, including the election of Class I directors, approval of the incentive plan amendment, and ratification of the independent registered public accounting firm.
The company’s definitive proxy statement on Schedule 14A outlines the agenda and voting procedures for the annual meeting, the proposals presented to stockholders, and information on the number of shares outstanding and entitled to vote. Regulation FD disclosures, such as the posting of an updated corporate presentation, are also reported via Form 8‑K and incorporated by reference.
Through Stock Titan, these filings are organized so that investors can quickly locate specific document types, such as current reports on material events, proxy materials, and other disclosures that complement Citius Oncology’s press releases about LYMPHIR™ (denileukin diftitox-cxdl) and its commercialization. AI-powered tools on the platform can assist users by summarizing lengthy documents, highlighting key items like equity plan changes, warrant issuances, and governance decisions, and helping readers understand how these regulatory filings relate to the company’s broader oncology strategy.
Citius Oncology, Inc. filed an 8-K to share positive topline Phase 1 data for LYMPHIR given before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. In 14 treated patients, investigators reported an 86% overall response rate, including 57% complete responses and 29% partial responses.
The investigator-initiated, open-label, dose-escalation study used single doses of LYMPHIR at 5, 7, or 9 µg/kg followed by low-dose chemotherapy and FDA-approved CAR-T products such as Yescarta, Breyanzi, or Kymriah. LYMPHIR was reported as well tolerated with no dose-limiting toxicities. The company notes the Phase 1 trial was not designed or powered to assess clinical efficacy or long-term outcomes.
LYMPHIR is already FDA-approved and commercially available in the U.S. for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy and was launched by Citius Oncology in December 2025. Management estimates the initial market for LYMPHIR exceeds $400 million and is underserved by existing therapies.
Citius Oncology, Inc. is filing a post-effective amendment to its Form S-1 to make available up to 6,818,182 shares of common stock underlying previously issued common warrants and 272,727 shares underlying placement agent warrants.
The offering consists solely of shares issuable upon exercise of outstanding warrants; the company would receive up to approximately $7.9 million if all outstanding warrants are cash‑exercised. The prospectus states the exercise price for the Common Warrant is $1.09 per share and for the Placement Agent Warrant is $1.65 per share. The prospectus notes 95,366,113 shares outstanding after giving effect to full exercise (assumption of full exercise). The company reported a last sale price of $1.21 per share on February 19, 2026. The amendment updates the prospectus for continuous resale under Rule 415 and confirms no new securities are being registered beyond the previously registered warrant‑underlying shares.
Citius Oncology reported that Armistice Capital, LLC and Steven Boyd beneficially own 8,078,404 shares, representing 9.79% of the common stock. The position is held through Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager; the Master Fund disclaims beneficial ownership arising from its lack of voting or dispositive power under the Investment Management Agreement.
The filing is a joint Schedule 13G/A signed by Steven Boyd on
Citius Oncology reported its first fiscal 2026 quarter, highlighted by the initial U.S. launch of LYMPHIR and the Company’s first commercial revenue. Revenue reached
Total operating expenses were
Citius Oncology reported its first product revenue after launching LYMPHIR for cutaneous T‑cell lymphoma, generating
The company still posted a net loss of
Citius Oncology, Inc. obtained stockholder approval by written consent to allow the issuance of common stock upon exercise of several warrant series tied to its December 2025 financing and prior offerings. The approval was granted on January 20, 2026 by majority holder Citius Pharmaceuticals, Inc., which owned 66,049,615 of 88,275,204 shares of common stock as of the record date.
The action permits the company to issue up to 16,513,762 shares on exercise of a December 2025 common warrant, up to 1,155,963 shares under December HCW warrants, and 660,550 shares under December Maxim warrants, all at exercise prices between $1.09 and $1.3625 per share. It also permits up to 6,818,182 shares under a July 2025 warrant and 5,142,858 shares under a September 2025 warrant, both repriced to $1.09 and having extended five‑year terms from stockholder approval.
The approval satisfies Nasdaq Listing Rule 5635(d), which requires stockholder consent for certain discounted issuances of 20% or more of outstanding stock. The written consent becomes effective on February 18, 2026; no meeting, proxy, or appraisal rights are provided to other stockholders.
Citius Oncology, Inc. obtained stockholder approval by written consent to issue shares of common stock upon exercise of several warrant series tied to a December 2025 financing and prior offerings. A majority holder, Citius Pharmaceuticals, Inc., which owned 66,049,615 shares, or about 74.8% of the 88,275,204 shares outstanding as of January 20, 2026, approved the issuances without a meeting. The actions cover up to 16,513,762 December Common Warrant shares, 1,155,963 placement agent warrant shares, and shares underlying amended July and September warrants for 6,818,182 and 5,142,858 shares, all at a $1.09 exercise price for the investor warrants. The company explains that potential exercises would significantly increase shares outstanding and dilute existing ownership, and that approval was required to comply with Nasdaq Listing Rule 5635(d). No vote or proxy is sought from other stockholders, and there are no appraisal rights.
Citius Oncology, Inc. is conducting a primary offering of 1,284,404 shares of common stock at $1.09 per share to a single institutional investor, raising gross proceeds of about $1.4 million. After placement agent fees and expenses, the company expects net proceeds of approximately $1.04 million, which it plans to use to support the commercial launch of its FDA‑approved CTCL therapy LYMPHIR and for general working capital needs.
Concurrently, Citius Oncology is issuing in private placements pre‑funded warrants to purchase up to 15,229,358 shares of common stock and an equal number of common warrants, plus additional warrants to buy up to 1,284,404 shares, all outside this prospectus. Following the stock sale, common shares outstanding are expected to be about 84.8 million, assuming no exercise of the new or existing warrants.
Citius Oncology, Inc. reported results from its 2025 annual meeting. Stockholders approved an amendment to the 2024 Omnibus Stock Incentive Plan, increasing common shares authorized for issuance under the plan from 15,000,000 to 30,000,000 shares.
Votes on the plan amendment were 74,220,840 for, 106,247 against, 14,688 abstaining, and 3,462,017 broker non-votes. Class I directors Myron Holubiak (74,305,221 for; 36,554 withheld; 3,462,017 broker non-votes) and Joel Mayersohn (74,312,668 for; 29,107 withheld; 3,462,017 broker non-votes) were elected for terms expiring in 2028. Stockholders also ratified Wolf & Company, P.C. as independent auditor with 77,690,844 for, 36,459 against, and 76,489 abstaining.
Citius Oncology furnished an updated Corporate Presentation under Regulation FD. The company posted the presentation on October 23, 2025 and attached it as Exhibit 99.1 to a Form 8-K. The company states that the information in Item 7.01, including Exhibit 99.1, is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as specifically referenced.
Citius Oncology’s common stock trades on the Nasdaq Capital Market under the symbol CTOR.